A nationwide recall has been issued for a specific batch of Xanax XR (alprazolam) 3 mg extended-release tablets. The distributor, Viatris Specialty LLC, initiated the recall on March 17, 2026, for lot number 8177156 (expiration date February 28, 2027) packaged in 60-tablet bottles with NDC 58151-506-91. The recall was expanded nationwide on April 15, 2026, after the tablets failed to meet dissolution specifications, according to the FDA.

The recall is classified as Class II, meaning use of the product may cause temporary or medically reversible adverse health effects, or the probability of serious harm is remote. Anyone who has been prescribed this specific lot of Xanax XR is advised to stop taking the medication immediately and dispose of it safely.

Xanax is a commonly prescribed benzodiazepine used to treat anxiety symptoms. The recall was voluntarily initiated by the firm and is currently ongoing, with distribution having occurred across the United States. No press release was issued for this recall.